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Introduction {#sec1}
============

Hematopoietic stem cells (HSCs) have the lifelong ability to self-renew and generate each of the blood lineages. In vertebrates, definitive hematopoiesis begins with de novo birth of HSCs from hemogenic endothelium along the ventral wall of the dorsal aorta in a conserved region known as the aorta-gonad-mesonephros (AGM) ([@bib8]). Studies in zebrafish and mammals have demonstrated that formation of the hematovascular niche is dependent on a signaling cascade between the Hedgehog (Hh) and the Notch pathways. This signaling controls placement of the stem cell leukemia (SCL) transcription factor and induction of the first definitive HSC marker, Runx1 ([@bib9], [@bib13], [@bib18]). Based on the conserved role of *runx1* in zebrafish ([@bib3], [@bib14], [@bib24]), we previously performed a chemical screen to identify regulators of HSC production ([@bib25]). We recently showed cholesterol-derived estrogens have a crucial role in establishing hemogenic endothelium boundaries ([@bib4]); the cholesterol derivative vitamin D was likewise identified as a candidate hematopoietic stem and progenitor cell (HSPC) regulator in the screen.

Vitamin D synthesis begins with the transformation of 7-dehydrocholesterol in the skin by UV radiation to generate the non-active vitamin D precursor cholecalciferol (D3). Some vertebrates, including teleosts (e.g., zebrafish), obtain D3 primarily from their diet ([@bib20]). D3 is modified by the cytochrome P450 enzyme 2R1 (CYP2R1) to generate 25-hydroxy vitamin D (25(OH)D3), the circulating form of vitamin D, which is then further hydroxylated by CYP27B1 to generate the active vitamin D metabolite, 1,25-dihydroxy vitamin D3 (1,25(OH)D3). Active 1,25(OH)D3 functions as the ligand for the vitamin D receptor (VDR), a member of the nuclear hormone receptor family, resulting in nuclear localization and transcriptional regulation ([@bib27]). Ligand binding also induces non-genomic cellular responses, including calcium uptake ([@bib23]). Zebrafish exhibit strong conservation of the vitamin D biosynthetic pathway and its downstream signaling cascade ([@bib7], [@bib19]).

Beyond the established role of 1,25(OH)D3 in VDR signaling, the biological function of vitamin D precursors in mediating non-VDR dependent events remains controversial. Mutations in 7-dehydrocholesterol reductase are associated with Hh defects in mammals ([@bib15]). Cell culture studies designed to isolate cholesterol derivatives affecting Hh signaling identified 3beta-hydroxysteroids, including D3, as negative Hh regulators in C3H/10T1/2 fibroblasts ([@bib2]). This study and others indicated exogenous addition of D3 may block Hh activity in a VDR-independent manner, potentially at the level of Smoothened ([@bib2], [@bib29]). Beyond these preliminary analyses, the mechanism of action of potential D3-mediated Hh regulation remains unclear and in vivo physiological relevance has not been elucidated.

Here, we demonstrate that exposure to elevated D3 (12--24 hours post fertilization \[hpf\]) negatively regulates hematovascular niche specification, decreasing HSPC numbers while sparing the gross development of the dorsal aorta. D3 inhibits the Hh signaling axis via binding in vivo to the recently described extracellular sterol-binding domain of Smoothened. Likewise, physiological accumulation of D3 mediated by inhibition of *cyp2r1* significantly reduced Hh activity and disrupted hemogenic niche specification, leading to low HSPCs. Together, these in vivo studies indicate inefficient vitamin D synthesis affects cellular specification and tissue maturation in the embryo, independent of reductions in 1,25(OH)D3 content, via negative regulation of the Hh signaling pathway.

Results {#sec2}
=======

Vitamin D Metabolites Differentially Regulate Definitive Hematopoiesis {#sec2.1}
----------------------------------------------------------------------

Vitamin D was isolated in a prior chemical screen in zebrafish as a potential modulator of HSPC gene expression ([@bib25]). To characterize the impact of vitamin D on definitive hematopoiesis, zebrafish embryos were exposed to the non-hydroxylated vitamin D precursor D3 and the active hydroxylated vitamin D metabolite, 1,25(OH)D3, between 12 and 36 hpf during the onset of HSPC formation. Treatment with D3 decreased expression of conserved HSPC markers *runx1* and *cmyb* as determined by whole-mount in situ hybridization (WISH) at 36 hpf ([Figures 1](#fig1){ref-type="fig"}A and 1B) and reduced HSPC-reporter (*Tg(runx1P2:eGFP)*) activity in the AGM ([Figure 1](#fig1){ref-type="fig"}C). In contrast, 1,25(OH)D3 increased both *runx1/cmyb* expression and Runx1 reporter activity ([Figures 1](#fig1){ref-type="fig"}A--1C), suggesting distinct modes of action. To confirm and quantify these findings, fluorescence-activated cell sorting (FACS) analysis was performed using *Tg(lmo2:dsRed);Tg(cmyb:gfp)* embryos, highlighting a broad population of HSPCs: D3 caused a 25% (p \< 0.01) decrease, while 1,25(OH)D3 elicited a 20% (p \< 0.01) increase in HSPC numbers ([Figure 1](#fig1){ref-type="fig"}D). To elucidate the cause of the differential regulation, embryos were treated for select intervals during hemogenic vascular endothelium specification (12--24 hpf) or definitive HSPC production (24--36 hpf). Whereas 1,25(OH)D3 increased *runx1/cmyb* WISH expression during either treatment window, the negative effect of D3 was predominantly observed with exposure between 12 and 24 hpf ([Figures 1](#fig1){ref-type="fig"}E and 1F). qPCR confirmed that statistically significant reductions in *runx1* were seen only after early D3 treatment, indicative of an effect on the HSPC niche ([Figure S1](#mmc1){ref-type="supplementary-material"}A). However, analysis of *flk1* expression indicated vasculogenesis was not grossly altered ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Early D3 exposure also had a minimal effect on the expression of *cyp24a1*, a direct VDR transcriptional target, while 1,25(OH)D3 was a potent activator ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Together, these data suggest D3 affects HSPC production via VDR-independent alterations in vascular niche specification.

D3 Exposure Inhibits Hh-Notch-Mediated Hemogenic Niche Specification {#sec2.2}
--------------------------------------------------------------------

In vertebrates, HSCs are born from hemogenic endothelium specified by highly orchestrated signaling events starting with the Hh pathway and ending with Notch activity ([@bib4], [@bib13], [@bib18]). Based on this pivotal role in vascular niche specification and prior studies describing potential inhibitory effects of D3, we hypothesized that D3 accumulation affected HSPC formation via inhibition of the Hh-Notch signaling cascade. To determine whether D3 could act to antagonize Hh-regulated developmental processes in vivo, the *Tg(gli-d:mcherry)* reporter line was used ([@bib28]). D3-treated embryos showed reduced Gli-reporter activity in the trunk region as determined by WISH ([Figures 2](#fig2){ref-type="fig"}A and 2B), similar to that seen with the Hh inhibitor cyclopamine. Co-treatment caused more severe inhibition, suggesting synergistic Hh antagonism ([Figures 2](#fig2){ref-type="fig"}A and 2B). FACS analysis of whole embryo disaggregates revealed a 54% (p \< 0.01) decrease in total Gli-reporter-positive cells by D3 treatment alone and a 91% (p \< 0.001) loss in combination with cyclopamine ([Figure 2](#fig2){ref-type="fig"}C). In contrast, no reduction in Hh activity was observed following 1,25(OH)D3 treatment by Gli-reporter WISH or FACS ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). To confirm the effect of D3 was independent of VDR signaling, a previously validated morpholino (MO) was employed ([@bib19]). No significant changes in Gli-reporter expression were seen with *vdra* knockdown ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D); however, morphants exposed to D3 still had reduced Hh activity ([Figure 2](#fig2){ref-type="fig"}D), supporting an alternate mechanism of action.

Consistent with a role for Hh upstream of Notch in vascular specification, D3 also diminished Notch-reporter activity (*Tg(EPV.Tp1CMmu.Hbb:EGFP)*) in the trunk vessels by WISH ([Figures 2](#fig2){ref-type="fig"}E and 2F), which was exacerbated by cyclopamine. D3-treated embryos had an expanded region of venous identity marked by *flt4* and concomitant decreases in arterial fate as indicated by *ephrinb2a* ([Figure S2](#mmc1){ref-type="supplementary-material"}E), consistent with published reports ([@bib18], [@bib4]). Reductions in arterial *ephrinb2a* and *notch3* ([Figure S2](#mmc1){ref-type="supplementary-material"}F), and the Hh target *ptc1*, with D3 exposure were confirmed by qRT-PCR. In contrast, neither addition of 1,25(OH)D3 nor *vdra* MO affected vascular niche and Hh target expression ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Finally, *scl+* hemogenic endothelium was profoundly lost in D3-treated embryos ([Figures 2](#fig2){ref-type="fig"}G and 2H), confirming disruption of the most proximal specification event downstream of Hh-Notch signaling to HSPCs.

20(S)-OHC Rescues D3-Mediated Inhibition of Smoothened and Hh Activity {#sec2.3}
----------------------------------------------------------------------

The G-coupled protein receptor Smoothened was previously identified as the target of cyclopamine-mediated Hh pathway inhibition; prior in vitro data suggested D3 may antagonize the same target ([@bib2]). Oxysterols, which stimulate Hh signaling ([@bib6]), were recently shown to bind in the extracellular cysteine-rich domain (CRD) of Smoothened, distinct from the heptahelical pocket cyclopamine targets ([@bib22]). To elucidate the mechanism of action of D3 on Hh activity in vivo, D3-treated embryos were exposed to Smoothened agonists SAG and 20(S)-hydroxycholesterol (20(S)-OHC) ([Figure 3](#fig3){ref-type="fig"}A). SAG binds to the heptahelical bundle, and can directly compete with cyclopamine ([@bib5]), whereas 20(S)-OHC binds the N-terminal extracellular CRD ([@bib22]). Co-treatment with SAG failed to block D3-mediated Hh inhibition as seen by Gli-reporter FACS ([Figure 3](#fig3){ref-type="fig"}B). In contrast, exposure to 20(S)-OHC preserved Hh signaling in the presence of D3 (p \< 0.05) ([Figure 3](#fig3){ref-type="fig"}B). Co-exposure to 20(S)-OHC also restored *ptc2* and *runx1* expression in D3-treated embryos by qRT-PCR (p \< 0.005) ([Figure 3](#fig3){ref-type="fig"}C), as well as HSPC induction by WISH ([Figures 3](#fig3){ref-type="fig"}D and 3E). These data indicate D3 inhibits Hh-dependent hemogenic endothelium specification in vivo by interactions with the Smoothened CRD.

Loss of *cyp2r1* Negatively Affects Hh Activity via D3/Smoothened Antagonism {#sec2.4}
----------------------------------------------------------------------------

Vitamin D synthesis begins concurrently with the onset of definitive hematopoiesis, as *cyp2r1* (25-hydroxylase), *cyp27b1* (1-hydroxylase), and *cyp24a1* (24-hydroxylase) are actively transcribed in the embryo by 24 hpf ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Mutations in *CYP2R1*, which catalyzes the first hydroxylation step in the enzymatic processing of D3 to 1,25(OH)D3, are associated with human vitamin D deficiency. To determine the potential physiological relevance of *cyp2r1* mutation-mediated D3 accumulation on Hh-dependent hematovascular specification, embryos deficient in *cyp2r1* were created by the clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated 9 (Cas9) system ([@bib10]). An allele with a 25-base pair deletion in exon 3, predicted to encode a truncated protein with a severely compromised active site, was produced ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Targeted deletion of *cyp2r1* diminished *runx1* expression (50% penetrance) compared to sibling controls ([Figure 4](#fig4){ref-type="fig"}A) while leaving *flk1+* vasculature grossly normal ([Figure 4](#fig4){ref-type="fig"}B). To confirm and quantify these observations, a *cyp2r1* MO was employed ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Morphants had a similar decrease in *runx1/cmyb* expression to that of *cyp2r1* mutants ([Figures 4](#fig4){ref-type="fig"}C and 4D), with FACS indicating a 21% (p \< 0.05) reduction in Flk1:dsRed+/cMyb:GFP+ HSCs ([Figure 4](#fig4){ref-type="fig"}E). Consistent with diminished Hh signaling due to D3 accumulation, *cyp2r1* mutants exhibited substantially reduced *ptc2* expression (77% penetrance) ([Figure 4](#fig4){ref-type="fig"}F). These effects were validated by Gli-reporter WISH following *cyp2r1*-MO knockdown ([Figures 4](#fig4){ref-type="fig"}G and 4H) and quantified as a 33% (p \< 0.01) decrease in Hh activity by FACS ([Figure 4](#fig4){ref-type="fig"}I). The *cyp2r1* morphants also had reduced Notch-reporter activity ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B) and artery or vein defects ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D), as seen with D3 exposure. In contrast, no inhibitory effect was seen in embryos injected with a MO to *cyp27b1* ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4G), further indicating that D3 accumulation, rather than loss of 1,25(OH)D3, caused the Hh phenotypes. To confirm the specificity of Cyp2r1 function in Hh regulation, morphants were co-injected with full-length zebrafish *cyp2r1* mRNA, mitigating the Gli-reporter phenotype ([Figure 4](#fig4){ref-type="fig"}J). Finally, to corroborate Smoothened antagonism, as found for D3, morphant embryos were treated with 20(S)-OHC and Gli-reporter activity was restored ([Figure 4](#fig4){ref-type="fig"}K). In sum, these data show that physiologically relevant reductions in vitamin D biosynthesis, occurring at the level of D3 hydroxylation via *cyp2r1* mutation, negatively affect Hh-dependent processes like hematovascular specification in vivo by accumulation of D3 and direct inhibition of the Smoothened CRD.

Discussion {#sec3}
==========

Beyond the role of vitamin D in calcium homeostasis, severe vitamin D deficiency in humans is associated with a variety of hematopoietic disorders, including anemia and extramedullary hematopoiesis ([@bib30]), due to alterations in the bone marrow microenvironment. *VDR*-deficient mice likewise display extramedullary hematopoiesis ([@bib11]). Vitamin D is also important in the immune system, specifically affecting T cell development and function ([@bib16]). Despite these findings, there is minimal investigation into the role of vitamin D regulation in the earliest stages of hematopoiesis. In this study, we demonstrate that vitamin D precursor D3 affects hemogenic vascular niche specification, affecting HSPC numbers during embryogenesis. Excess D3 derived from exogenous exposure or insufficient Cyp2r1 function diminished Hh signaling and disrupted Hh-regulated mesodermal cell fate. Significantly, these effects were not phenocopied by 1,25(OH)D3 or dependent on VDR activity. Rather, our data indicate that D3 acts directly on Smoothened at the recently defined extracellular sterol-binding domain ([Figure 3](#fig3){ref-type="fig"}A). The strong synergy observed between D3 and cyclopamine toward Hh inhibition in vivo is consistent with prior mechanistic studies in which 20(S)-OHC and SAG mediated allosteric interactions between the CRD and the heptahelical binding domains of Smoothened to result in maximum pathway activation ([@bib21]). Finally, the *cyp2r1* loss-of-function studies demonstrate a physiological role for D3 in Hh pathway inhibition. These findings are intriguing in the context of human disease, because *CYP2R1* mutations result in vitamin D-deficient rickets marked by skeletal abnormalities, with low levels of 25(OH)D3 but relatively normal levels of 1,25(OH)D3 ([@bib1]). While it has been postulated that maintenance of 1,25(OH)D3 sufficiency is due to increased parathyroid hormone activity and alterations in *CYP27B1* and *CYP24A1* function, it will be important to re-evaluate whether developmental abnormalities in these patients are partially due to reductions in Hh signaling caused by D3 accumulation. It will also be interesting to examine interplay between abnormal vitamin D biosynthesis and Hh signaling in cancer, specifically in tissues where both pathways intersect. In summary, we elucidated the physiological consequences of abnormal vitamin D biosynthesis at the level of D3 hydroxylation on hematovascular specification and characterized the mechanism of action in vivo as an antagonistic interaction of D3 with Smoothened and the Hh signaling pathway.

Experimental Procedures {#sec4}
=======================

Zebrafish Husbandry {#sec4.1}
-------------------

Zebrafish were maintained in accordance with the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee. The following lines were used: AB, Tuebingen, *cyp2R1* mutant, *Tg(lmo2:dsred)* ([@bib31]), *Tg(cmyb:eGFP)* ([@bib25]), *Tg(flk1:dsRed2ex)* ([@bib12]), *Tg(runx1P2:eGFP)* ([@bib17]), *Tg(Gli-d:mCherry)* ([@bib28]), and *Tg(EPV.Tp1CMmu.Hbb:EGFP)* ([@bib26]).

Chemical Treatments {#sec4.2}
-------------------

Zebrafish embryos were exposed to chemical modulators in E3 fish medium from 12 to 36 hpf in multi-well plates. The following compounds were used: D3 (50 μM, Enzo), 1,25(OH)D3 (10 μM, Cayman Chemical), cyclopamine (50 μM, LC Laboratories), 20(S)-OHC (10 μM, Tocris), and SAG (10 μM, Tocris). Treated embryos were analyzed by WISH using previously published probes to *runx1*, *cmyb*, *flk1*, *gfp*, *flt4*, *ephrinb2a*, and *ptc2* ([@bib4]) and established methods (<https://zfin.org/ZFIN/Methods/ThisseProtocol.html>). Data were qualitatively analyzed and graphically depicted as the percentage falling into each of three phenotypic expression bins. "Medium" expression was set as the most representative phenotype in the normal bell-curve distribution of each cohort of controls (n ≥ 3 replicate clutches). Images were acquired using a Zeiss Axio Imager A1/AxioCam MRc using AxioVision LE software.

MO and mRNA Injections {#sec4.3}
----------------------

MOs (Gene Tools) were injected at the one-cell stage: *cyp2r1*MO1-5′-TGATCGATATCATCTTAGATGCAAA-′3, *cyp2r1*MO2-5′-TTCCATAAGGAACCACTTACCTCCC-3′, *cyb27b1*MO-5′-TGAAGCACCATCATCATCCTCCTGC-3′, and *vdra*MO-5′-ACGGCACTATTTTCCGTAAGCATCC-3′. Splicing efficiency of the *cyp2r1* MO was determined by qRT-PCR using the following primer set: Cyp2r1Fwd-5′-ATGATATCGATCAAACGCTTAACATCACCG-3′ and Cyp2r1Rev-5′-CAGAAATCCTCACAAACATCCTCCGCTGGC-3′. Specificity was tested by injection of in vitro transcribed full-length *cyp2r1* mRNA (100 ng/μl). Synthesis was performed using mMessage mMachine T7 and the Poly(A) Tailing Kit (Life Technologies).

Embryo Dissociation and FACS Analysis {#sec4.4}
-------------------------------------

Fluorescent embryos (5 embryos/sample × 4 replicates/condition) were incubated in 0.5 mg/ml of Liberase (Roche) with gentle agitation at 37°C for 2 hr and then manually dissociated by pipetting, filtered, washed, and resuspended in 1× PBS. Samples were treated with SYTOX Red dead cell stain (5 nM, Life Technologies) and analyzed using a BD Biosciences FACSCanto II and LSRII 5 SORP. Data were processed on Flojo X software (Tree Star), and statistics (two-tailed Student's t test) were performed using Prism 6 (GraphPad).

qRT-PCR Performance {#sec4.5}
-------------------

Total RNA (40 pooled embryos/condition) was purified using the RNAqueous Total RNA isolation kit, followed by DNase-I treatment, and used to generate cDNA using the Superscript III First Strand Synthesis Supermix (Life Technologies). qRT-PCR was performed using SYBR Green PCR Master Mix (Life Technologies) on a Bio-Rad CFX384. Samples were run in triplicate with \>2 biological replicates/condition using primer sequences in [Table S1](#mmc1){ref-type="supplementary-material"}. RT-PCR Miner (<http://ewindup.info/miner/>) was used for analysis, with statistics as explained earlier.

Cyp2r1 Mutation Generation and Validation {#sec4.6}
-----------------------------------------

Guide RNA (gRNA) targeting *cyp2r1* was designed using Zifit Targeter (<http://zifit.partners.org>). Oligos to the *cyp2r1* gRNA sequence 5′-GGACTTCTGAACTGCAAATA-3′ were annealed, cloned into pT7-gRNA (Addgene \#46759), and in vitro transcribed using MEGAshortscript-T7 (Life Technologies). Cas9 RNA (100 ng), transcribed from pT3Ts-nls-zCas9-nls (Addgene \#46757) using mMessage mMachine T3, as explained earlier, was co-injected with gRNA-*cyp2r1* (50 ng) at the one-cell stage and raised to adulthood. *cyp2r1*-F1 mutants were identified by PCR amplification flanking the target sequence: Cyp2r1CrispF-5′-ATTGCTGTTTGACCAGTCATCCCTGATCGA-3′, Cyp2r1CrispR-5′-CAGGGGAAGGCGTTGTACAGGAAAGCCCAA-3′, and EagI (NEB) restriction digest. DNA sequencing confirmed the mutant *cyp2r1* allele.
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====================
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![Vitamin D Metabolites Have Differential Effects on HSC Formation\
(A) Exposure to D3 (50 μM) decreased *runx1/cmyb* expression by WISH at 36 hpf, and 1,25(OH)D3 (10 μM) increased expression. Scale bar, 100 μm.\
(B) Qualitative phenotypic distribution of embryos from (A) scored with low, medium, or high *runx1/cmyb* expression in the AGM (n \> 50 embryos/condition).\
(C) Runx1:GFP embryos exhibited either diminished or enhanced expression with D3 or 1,25(OH)D3 exposure, respectively. Scale bar, 100 μm.\
(D) FACS analysis of double-positive HSPCs in Lmo2:dsRed/cMyb:GFP embryos confirmed a 25% (^∗^p = 0.014) decrease with D3 versus a 20% (^∗∗^p = 0.029) increase with 1,25(OH)D3 compared to controls (5 embryos/sample × 4 replicates/condition). Error bars, mean ± SD.\
(E) D3 treatment during hemogenic niche specification (12--24 hpf) or HSC induction (24--36 hpf) only decreased *runx1/cmyb* by WISH in the early exposure window, whereas 1,25(OH)D3 increased expression during either treatment period. Scale as in (A).\
(F) Qualitative phenotypic distribution of embryos from (E) scored for *runx1/cmyb* as in (B) (n \> 20 embryos/condition).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![D3 Negatively Regulates Hh-Mediated Vascular Niche Specification\
(A) Gli:mCherry expression was decreased in D3-treated embryos compared to controls by WISH. Cyclopamine co-treatment caused synergistic reduction. Scale bar, 200 μm.\
(B) Qualitative phenotypic distribution of embryos from (A) scored for *gli:mcherry* (n \> 20 embryos/condition).\
(C) Gli:mCherry FACS showed significant decreases in Hh responsive cells in D3 (54%, ^∗^p = 0.006), cyclopamine (70%, ^∗∗^p = 0.001), or co-treated embryos (91%,^∗∗∗^p = 0.001) (5 embryos/sample × 4 replicates/condition). Error bars, mean ± SD.\
(D) Qualitative phenotypic distribution of *gli:mcherry* expression in *vdra* morphants occurred in the presence or absence of D3 treatment (n \> 20 embryos/condition).\
(E) D3 reduced Notch reporter activity in intersomitic and axial vessels, similar to cyclopamine, by WISH. Co-treatment exacerbated Notch inhibition. Scale bar, 100 μm.\
(F) Qualitative phenotypic distribution of embryos from (D) scored for *Notch-GFP* (n \> 20 embryos/condition).\
(G) SCL-GFP embryos treated with D3 (12--30 hpf) had reduced *scl+* hemogenic endothelium by WISH for GFP. Scale as in (E).\
(H) Qualitative phenotypic distribution of embryos from (F) scored for *scl:GFP* (n \> 10 embryos/condition).\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![D3 Antagonizes Hh Signaling via Interaction with the Extracellular Domain of Smoothened\
(A) Diagram depicts the sites of action of Hh pathway modifiers cyclopamine, SAG, and 20-OHC on the Smoothened receptor. The presumptive site of D3 action (red) is shown.\
(B) FACS of Gli-reporter embryos showed D3 decreased Hh activity (^∗^p = 0.002). SAG co-treatment (5 μM) did not alter the effect of D3, while 20(S)-OHC (10 μM) partially blocked Hh inhibition (^∗∗^p = 0.040) (5 embryos/sample × 4 replicates/condition). Error bars, mean ± SD.\
(C) Co-treatment with 20(S)-OHC corrected D3-mediated reductions in *ptc2* (^∗^p = 0.019) and *runx1* (^∗∗^p = 0.003) by qPCR (40 pooled embryos/condition × 3 replicates). Error bars, mean ± SD.\
(D) 20(S)-OHC restored *runx1* expression in D3-treated embryos. Scale bar, 100 μm.\
(E) Qualitative phenotypic distribution of embryos from (D) scored for *runx1* (n \> 20 embryos/condition).](gr3){#fig3}

![Cyp2r1 Inhibition and Failed D3 Hydroxylation Elicits Hh-Related Defects in HSPC Production\
(A) WISH for *runx1* showed *cyp2r1* mutation results in HSPC defects. Scale bar, 100 μm.\
(B) WISH for *flk1* revealed minimal impact of *cyp2r1* loss on trunk vessels. Scale as in (A).\
(C) *cyp2r1* morphants had diminished *runx1/cmyb* expression. Scale bar, 50 μm.\
(D) Qualitative phenotypic distribution of embryos from (C) scored for *runx1* (n \> 30 embryos/condition).\
(E) Flk:dsRed+/cMyb:GFP+ FACS indicated a 21% (^∗^p = 0.0328) decrease in HSCs in *cyp2r1* morphants (5 embryos/sample × 4 replicates/condition). Error bars, mean ± SD.\
(F) In *cyp2r1* mutants, *ptc2* WISH showed Hh signaling was affected by endogenous D3 accumulation (77% penetrance). Scale as in (A).\
(G) WISH for Gli-reporter expression in *cyp2r1* morphants confirmed low Hh activity was correlated with ineffective D3 hydroxylation. Scale bar, 100 μm.\
(H) Qualitative phenotypic distribution of embryos from (G) scored for *mcherry* expression (n \> 40 embryos/condition).\
(I) FACS of *cyp2r1*-MO-injected Gli-reporter embryos revealed a 33% (^∗^p = 0.0065) decrease in Hh activity (n value and error bars as in E).\
(J) Gli:mCherry FACS showed co-injection of zebrafish *cyp2r1* mRNA-rescued, *cyp2r1*-MO-meditated decreases in Hh activity (^∗^p = 0.009) (n value and error bars as in E).\
(K) 20(s)-OHC-rescued defects in Hh activity caused by *cyp2r1* knockdown as shown by FACS of the Gli-reporter line (^∗^p = 0.0005) (n value and error bars as in E).\
See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
